

Disappointing Worldwide Obesity Treatment Statistics: The hCG Method Deserves an Unbiased Review

Daniel Oscar Belluscio*

Department of Obesity, hCG Research Center, Buenos Aires, Argentina

ABSTRACT

The obesity epidemic is devastating the social and healthcare structure of developed and underdeveloped nations. In developed countries, obesity accounts for 1 out of 3 individuals, the medical care costs of obesity in the United States, for example, are high. In 2008 dollars, these costs were estimated to be \$147 billion. Annual nationwide productive cost of obesity and obesity-related absenteeism ranges in between \$3.38 billion (\$79 per obese individual) and \$6.38 billion (\$132 per obese individual). Despite this thrilling data, obesity treatment results remain disappointing: gathered data is depressing, from surgical to non-surgical procedures, Short term weight loss does not result in long term weight loss.

Keywords: Obesity; hCG method; Healthcare

THE hCG METHOD FOR OBESITY TREATMENT: AN OVERLOOKED ALTERNATIVE

Despite their critics, the hCG (Human Chorionic Gonadotropin) and diet protocol survived for the past 65 years: clear evidence that the procedure out passed the test of time. About seventy years ago his author: Dr. ATW Simeons was the first Physician to suggest that obesity is not related to weight as registered on a bath scale, but in the increased amount of total body fat [1].

The cause for that abnormal fat accumulation does not lie in the mouth or the stomach, but a neuropeptide disorder at a hypothalamic level. Recent research on leptins, adiponectins, and neuropeptides sustain his working hypothesis. The method provided relief and excellent results to hundreds of thousands of overweight/obese patients worldwide [2-3].

By 1991, I have developed and published my obtained results using an oral formulation of hCG.

Consequently, I have reported over the Internet our research results, both in humans and experimental animals [4,5].

TO SUMMARIZE OUR CONCLUSIONS

In Human Volunteers:

1. Compared to placebo-treated, volunteers submitted to the

hCG+diet procedure lost more body fat than their placebo counterparts

2. Perfectly tolerated a Very-Low-Calorie Diet.
3. Rapidly improved their blood sugar levels and blood pressure.
4. No side effects

In Experimental Animals: Compared to Placebo-treated: hCG+Diet Animals Significantly:

1. Lost more body fat.
2. Decreased plasmatic Leptin levels
3. Increased adiponectin levels.
4. Decreased blood sugar levels.

Besides, hCG administration has a protective effect on pancreatic beta cells, improves intractable chronic pain, decreased blood pressure more efficiently than patients treated only with hypocaloric diet.

BIOGRAPHY

Dr. Daniel Oscar Belluscio, Nationality: Argentina;

Medical qualifications of Doctor Daniel Belluscio [5-8];

- Graduated from the University of Buenos Aires, Argentina (1974)

*Corresponding to: Daniel Oscar Belluscio, Department of Obesity, hCG Research Center, Buenos Aires, Argentina, Tel: +5491130241883; E-mail: drbelluscio@oralHCG.com

Received: May 11, 2021; Accepted: August 20, 2021; Published: August 27, 2021

Citation: Belluscio DO (2021) Disappointing Worldwide Obesity Treatment Statistics: The hCG Method Deserves an Unbiased Review. J Diabetes Metab. 12:894.

Copyright: 2021 © Belluscio DO. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

- Specialist in Internal Medicine
- Specialist in Bariatric Medicine
- Researcher - Bellevue Klinik - Switzerland.
- Researcher - Marbert Laboratories - Germany
- Clinical Researcher Planas - Barcelona - Spain
- Visitor - University of Utrecht - The Netherlands
- Visitor - Institute of Medicine II - Gothenburg - Sweden
- Visitor - Serono Laboratories - Milan - Italy
- Director of ISAUC (International Society for Alternative Uses of humanChoriogonadotropin)
- Director - Indexmedico
- Founding Director of The Oral hCG Research Center, the world's most prestigious and recognized medical institution for hCG treatment.

Dr. Belluscio devoted most of his medical career to the study of hCG for weight loss. For several years he was a researcher at Bellevue Klinik, Switzerland, an institution with the most impressive records of treated patients with hCG (15,000) for obesity and overweight. He traveled to the U.S., Mexico, Sweden, Italy, Germany, and Israel, lecturing on the method. In 1987 he founded The Oral hCG Research Center, an institution devoted to the utility of hCG for obesity treatment. Records show that the center used the hCG Oralmethod in over 9.000 patients. Back in 1991, he developed an oral hCG formulation, whichdemonstrated its effectiveness in a series of Double-blind studies. Together with Dr. Vogt, Director of Bellevue Klinik, published several reports on the method aimed at Healthcare Professionals, and articles on the subject for the general public. Oral hCG has been registered as a TM, with patents published and pending, both in Argentina and the United States [9-13]. These patents and registrations include the brand: oral hCG, as well as various pharmaceutical sublingual formulations. These formulations have been used in his private practice for his patients for over 25 years. Currently, Dr. Belluscio participates in international medical congresses and gives lectures

and lectures to the global medical community on the hCG Protocol and the formula he has developed.

REFERENCES

1. Carne S. The action of chorionic gonadotropin in the obese. *Lancet* 1954; 267:946-947.
2. Obesity: How to Diagnose and Treat an Epidemic. Retrieved from: <https://reference.medscape.com/slideshow/obesity-6009299>
3. Obesity: global epidemiology and pathogenesis. Retrieved from: <https://www.nature.com/articles/s41574-019-0176-8>
4. <https://www.cdc.gov/obesity/adult/causes.html>
5. <https://slideplayer.com/slide/2803151/>
6. Asher WL, Harper HW. Effect of human chorionic gonadotropin on weight loss, hunger and feeling of well-being. *Am J Nutr* 1973; 26: 211-218.
7. Belluscio D, Ripamonte L. The use of oral Human Chorionic Gonadotropin (HCG) for the treatment of obesity: A double-blind study. *Rev Inst Med Sucre* 1999; 64: 14-21.
8. Belluscio D, Ripamonte L. Utility of an oral presentation of HCG for the Management of Obesity. A double bind study. *The original internist* 2009.
9. Bosch B, Venter I, Stewart RI, Bertram SR. Human chorionic gonadotropin and weight loss. A double-blind, placebo-controlled trial. *S. Afr Med J* 1990; 77:185-189.
10. Belluscio D. The hypothalamic genesis of obesity. *Nat Prec* 2012; 7031: 1.
11. Belluscio D, Lago N, Klimovsky E, Berdeal M, Federico A. Metabolic Activity of Human Chorionic Gonadotropin (HCG) on Glycemia and Leptinemia in Experimental Animals Fed a Cafeteria Diet. *Nat Prec* 2011; 5781: 1.
12. Belluscio D, Klimovsky E, Kaniuk A, Vaney S. Intrarectal administration of HCG (Human Choriogonadotropin) and fat loss as assessed by Dual energy X-ray absorptiometry (DXA) in experimental animals. *Nat Prec* 2012; 7074: 2.
13. Belluscio D, Vaney SA. The influence of different excipients and storage procedures on HCG (human Corionic Gonadotropin) as evidenced by spectrophotometry. *Nat Prec* 2011; 5919: 1.